Goodwin’s Life Sciences Capital Markets team advised BridgeBio (BBIO) Pharma on its offering of 1.75% Convertible Senior Notes due 2031. The offering priced at $500M, plus the full exercise of the initial purchasers’ option to purchase an additional $75M of notes. The initial conversion price of the notes featured a premium of 45% up from the reference price of $34.35. BridgeBio used a portion of the net proceeds from the offering to repurchase shares of its common stock and repay outstanding indebtedness.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BBIO:
- BridgeBio Pharma Strengthens Financial Position with Note Issuance
- BridgeBio price target raised to $46 from $45 at BofA
- Strong Launch and Strategic Initiatives Propel BridgeBio Pharma’s Growth Prospects
- Positive Outlook for BridgeBio Pharma: Strong Demand for Attruby and Promising Pipeline Fuel Buy Rating
- BridgeBio price target raised to $52 from $49 at Scotiabank